Logo

Incyte Entered into a Collaboration and License Agreement with CMS to Develop and Commercialize Ruxolitinib in Greater China and Southeast Asia

Share this

Incyte Entered into a Collaboration and License Agreement with CMS to Develop and Commercialize Ruxolitinib in Greater China and Southeast Asia

Shots:

  • Incyte to receive an up front & is eligible to receive development, regulatory & commercial milestones along with royalties on net sales of the licensed product in CMS’ territory
  • CMS to get an exclusive license to develop & commercialize the product and a non-exclusive license to manufacture ruxolitinib & other topical formulations for autoimmune & inflammatory dermatologic diseases in mainland China, Hong Kong, Macau, Taiwan & certain countries in Southeast Asia
  • The collaboration uses Incyte’s Dermatology expertise to advance ruxolitinib for immune-mediated dermatologic conditions. If ruxolitinib is approved, it will be an innovative therapeutic option & provide an access to patients & healthcare providers for treatment in Greater China

Ref: Businesswire Image: Incyte

Click here to­ read the full press release 

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions